Q2 FY2026 EarningsQ2 FY26 results beat revenue expectations ($1.63M vs. $1.38M consensus) and GAAP EPS expectations (-$0.15 vs. -$0.16 consensus). Research and development expenses rose to $18.1M as clinical trials for ATI-052 and ATI-9494 accelerated. Management reaffirmed a strong cash runway through late 2028, bolstered by a post-quarter $40.2M ATM equity raise, providing sufficient liquidity for multiple upcoming Phase 2 data readouts in H2 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aclaris Therap(ACRS) the Revenue is 1.629 M (-8.33%), Beat estimate;the EBIT is -24.24 M (-31.67%), Miss estimate;the EPS is -0.15 (-15.38%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B8.33%
0.00B22.18%
+0.00B13.85%
EBITMiss expectations
-0.02B31.67%
-0.02B24.95%
-0.00B6.72%
EPSExceed expectations
-0.1515.38%
-0.1623.08%
+0.01007.70%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf